Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 77.72% | 38.94% | -11.85% | -30.51% | -53.04% |
| Total Depreciation and Amortization | -4.21% | -4.95% | -6.96% | -13.01% | -17.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.72% | -28.05% | -1.65% | -44.13% | -63.37% |
| Change in Net Operating Assets | 17.31% | -238.26% | -241.50% | -230.78% | -223.79% |
| Cash from Operations | 70.59% | 28.91% | -41.74% | -76.77% | -125.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.00% | 122.22% | 0.00% | -102.63% | -103.23% |
| Cash from Investing | 120.00% | 122.22% | 0.00% | -102.63% | -103.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.44% | -3.53% | 2.10% | 12.02% | 20.32% |
| Issuance of Common Stock | -47.37% | -52.36% | -54.65% | -54.38% | -54.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 48.95% | 50.48% | 51.19% | 52.18% | 53.17% |
| Cash from Financing | -46.87% | -52.51% | -56.12% | -55.77% | -55.42% |
| Foreign Exchange rate Adjustments | -33.30% | -17.17% | -5.43% | -29.01% | -107.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.83% | -33.71% | -328.67% | -298.02% | -279.62% |